Menzies Institute for Medical Research, Hobart, Australia; Baker Heart and Diabetes Institute, Melbourne, Australia.
Royal Hobart Hospital, Hobart, Australia.
JACC Cardiovasc Imaging. 2019 Nov;12(11 Pt 1):2103-2111. doi: 10.1016/j.jcmg.2018.08.017. Epub 2018 Oct 17.
The aim of this study was to evaluate the relative value of baseline and follow-up echocardiographic assessment of pulmonary artery systolic pressure (PASP) and right ventricular (RV) function in assessing response to vasodilator therapy in pulmonary arterial hypertension (PAH).
Routine follow-up of PASP and RV function is widely obtained in patients undergoing treatment for PAH, but the value of this reassessment is uncertain.
Of 162 prospectively recruited patients with PAH, 96 were included in this analysis of patients with ≥3 sequential echocardiographic studies. PASP and RV function (including right ventricular free wall strain [RVFWS]) were measured at baseline and on follow-up 2-dimensional echocardiography. Univariate and multivariate Cox regression with nested models was used to determine incremental and independent predictors of all-cause mortality.
Changes between visits were minimal for all parameters (RVFWS, p = 0.46; RV end diastolic area, p = 0.48; tricuspid annular plane systolic excursion, p = 0.32; PASP, p = 0.66; right atrial area, p = 0.39; and inferior vena cava, p = 0.25). Over 3 years of follow-up, 29 patients died. Baseline RVFWS was an independent predictor of outcome (hazard ratio [HR]: 0.90; 95% confidence interval [CI]: 0.83 to 0.97; p = 0.007), incremental to PASP and other clinical covariates (C statistic = 0.74, p = 0.001). Those who died showed no differences in RVFWS (p = 0.50), PASP (p = 0.90), and tricuspid annular plane systolic excursion (p = 0.83) between visits. When baseline measures and follow-up time were accounted for, mean changes in RVFWS (HR: 0.78; 95% CI: 0.63 to 0.96; p = 0.002), right atrial area (HR: 1.20; 95% CI: 1.07 to 1.40; p = 0.003), and inferior vena cava (HR: 66.5; 95% CI: 8.5 to 520.5; p < 0.001) over follow-up were significant in predicting outcome.
In PAH, baseline RV function (RVFWS) is a strong predictor of outcome, independent of PASP. Changes throughout therapy appear minimal, and only changes in RVFWS, inferior vena cava, size, and right atrial area were associated with outcome.
本研究旨在评估基线和随访时超声心动图肺动脉收缩压(PASP)和右心室(RV)功能评估在肺动脉高压(PAH)患者对血管扩张剂治疗反应中的相对价值。
在接受 PAH 治疗的患者中,广泛获得 PASP 和 RV 功能的常规随访,但这种再评估的价值尚不确定。
在 162 例前瞻性招募的 PAH 患者中,有 96 例患者符合≥3 次连续超声心动图研究的分析要求。在基线和二维超声心动图随访时测量 PASP 和 RV 功能(包括右心室游离壁应变[RVFWS])。使用单变量和多变量 Cox 回归与嵌套模型来确定全因死亡率的增量和独立预测因素。
所有参数(RVFWS,p=0.46;RV 舒张末期面积,p=0.48;三尖瓣环平面收缩期位移,p=0.32;PASP,p=0.66;右心房面积,p=0.39;和下腔静脉,p=0.25)的随访期间变化很小。在 3 年的随访期间,有 29 名患者死亡。基线 RVFWS 是结局的独立预测因素(风险比[HR]:0.90;95%置信区间[CI]:0.83 至 0.97;p=0.007),优于 PASP 和其他临床协变量(C 统计量=0.74,p=0.001)。死亡患者在 RVFWS(p=0.50)、PASP(p=0.90)和三尖瓣环平面收缩期位移(p=0.83)的随访中没有差异。当考虑基线测量值和随访时间时,RVFWS(HR:0.78;95%CI:0.63 至 0.96;p=0.002)、右心房面积(HR:1.20;95%CI:1.07 至 1.40;p=0.003)和下腔静脉(HR:66.5;95%CI:8.5 至 520.5;p<0.001)的平均值变化在预测结局方面具有显著意义。
在 PAH 中,基线 RV 功能(RVFWS)是结局的有力预测因素,独立于 PASP。整个治疗过程中的变化似乎很小,只有 RVFWS、下腔静脉、大小和右心房面积的变化与结局相关。